BrainsWay Announces Virtual Analyst & Investor Day Event
BURLINGTON, Mass. and JERUSALEM – BrainsWay Ltd. (NASDAQ: BWAY) is excited to announce a virtual Analyst & Investor Day scheduled for December 1. This event promises to illuminate various facets of the company's growth strategy, focusing particularly on the groundbreaking Deep TMS™ treatment.
Highlighting Industry Leaders
The virtual event will feature insights from Owen Scott Muir, MD, DFAACAP, a co-founder and Chief Medical Officer of Radial Health. Dr. Muir will share his clinical experiences with Deep TMS™, emphasizing the pressing needs in mental health treatment. Additionally, the event will host Michael Gershenzon, CEO of Stella MSO, an organization renowned for its services across more than 20 mental health clinics in the U.S. and Israel, who will discuss BrainsWay's strategic investment in Stella.
What is Deep TMS™?
Deep TMS™ is an innovative treatment that employs magnetic fields to stimulate specific brain regions associated with mental health disorders. It is designed to enhance neural connectivity and improve symptoms related to various conditions such as depression, OCD, and smoking addiction. This noninvasive treatment represents a significant advancement in psychiatric care, especially for those who haven't found relief through traditional methods.
Engaging with the Audience
Participants can look forward to a live question-and-answer session following the formal presentations, allowing attendees to engage directly with the speakers and delve deeper into the topics discussed.
About Owen Scott Muir, MD, DFAACAP
Dr. Muir, a renowned psychiatrist, has dedicated his career to the field of advanced neuromodulation. His work includes investigating the efficacy of Deep TMS™ and its role in addressing severe mental health challenges. His contributions to mental health are significant, including educational content that reaches millions, demonstrating his commitment to improving patient outcomes across various platforms.
About BrainsWay
Founded in 2003, BrainsWay is at the forefront of neurostimulation technology, leading in the field of mental health treatments. The company boasts FDA clearances for three major insomnia disorders, showcasing its commitment to rigorous clinical evidence and patient care innovation. Research and ongoing clinical trials are integral to its mission of expanding access to Deep TMS treatments worldwide, thereby enhancing the quality of life for countless individuals suffering from mental health issues.
Frequently Asked Questions
What will be covered during the virtual Analyst & Investor Day?
The event will focus on BrainsWay’s growth strategy and advancements in Deep TMS™, with insights from industry leaders.
How can I participate in the virtual event?
Registration details are typically provided on BrainsWay’s official website or announcements ahead of the event date.
What is the significance of Deep TMS™?
Deep TMS™ represents a breakthrough in treating mental health conditions by using noninvasive methods that target neural networks to alleviate symptoms.
Who are the featured speakers at the event?
Owen Scott Muir, MD, and Michael Gershenzon are among the speakers who will share their expertise and experiences related to Deep TMS™.
How can I learn more about BrainsWay's treatments?
For comprehensive information, please visit the BrainsWay website or consult their published resources on neurostimulation therapies.